Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $7.00 target price on the stock.
Separately, Maxim Group assumed coverage on shares of Ocugen in a research report on Tuesday, October 15th. They set a “buy” rating and a $4.00 target price on the stock.
Get Our Latest Report on Ocugen
Ocugen Stock Down 1.8 %
Ocugen (NASDAQ:OCGN – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.14 million during the quarter. During the same quarter in the prior year, the firm posted ($0.10) EPS. Research analysts forecast that Ocugen will post -0.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Ocugen
A number of large investors have recently modified their holdings of OCGN. Headlands Technologies LLC bought a new stake in Ocugen during the first quarter worth $66,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Ocugen in the 1st quarter worth $132,000. Tidal Investments LLC purchased a new stake in shares of Ocugen in the first quarter valued at about $108,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Ocugen in the second quarter valued at about $35,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Ocugen by 2,760.5% during the second quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock valued at $1,165,000 after purchasing an additional 725,536 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
See Also
- Five stocks we like better than Ocugen
- The 3 Best Blue-Chip Stocks to Buy Now
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Airline Stocks – Top Airline Stocks to Buy Now
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.